The American company Eli Lilly and the Canadian AbCellera are working on an antibody treatment to combat the coronavirus. He expects results in late June.
Increase your business, Not your inbox
Stay up to date and subscribe to our daily newsletter now!
Read for 2 min
Eli Lilly and Company reported that a first group of patients in an early-stage study received doses to test a possible treatment for COVID-19, the world’s first study of antibody treatment for the disease.
The first phase of the test assesses whether the therapy is safe and well tolerated. It is expected that if the results are positive, Treatment available until late June.
The first patients with Covid-19 to be treated with this therapy will be hospitalized at the Grossman School of Medicine at New York University in New York, Cedars-Sinai Hospital in Los Angeles, and Emory University in Atlanta. .
The treatment was developed in collaboration with AbCellera, a Canadian biotech company. This company took a blood sample from one of the first patients in the United States to recover from COVID-19, and the company sorted millions of cells from that patient to find hundreds of antibodies.
Scientists from AbCellera and the National Institute of Allergy and Infectious Diseases vaccine research center chose what they thought were most effective, and Lilly scientists developed the treatment known as monoclonal antibody therapy. Treatment was called LY-CoV555.